LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Asset Writedowns and Impairment of $82000.0 for Q2 2025, down 99.39% quarter-over-quarter from $13.3 million in Q4 2023.
LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Asset Writedowns and Impairment for 2 consecutive years, with $82000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $82000.0; the TTM figure through Mar 2026 stood at $82000.0 (changed N/A YoY), while the FY2025 annual figure was $82000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment slipped to $82000.0 in Q2 2025 per LENZ's latest filing, from $13.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $13.3 million in Q4 2023 and bottomed at $82000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 414,000.00 |
| Mar 31, 2026 | 414,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Dec 31, 2023 | 13.35 Mn |
| Dec 31, 2023 | 13.35 Mn |
| Sep 30, 2023 | 7.22 Mn |
| Sep 30, 2023 | 7.22 Mn |